In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to EAPC Ivory (& above) Members, Fellows of the ESC and Young combined Members

Assessment of the factors of angiogenesis in patients with arterial hypertension and coronary artery disease

Session Poster Session 3

Speaker Svetlana Glova

Congress : EuroPrevent 2019

  • Topic : hypertension
  • Sub-topic : Hypertension - Treatment
  • Session type : Poster Session
  • FP Number : P764

Authors : SE Glova (Rostov-on-Don,RU), LA Khaisheva (Rostov-on-Don,RU), SV Shlyk (Rostov-on-Don,RU)

Authors:
SE Glova1 , LA Khaisheva1 , SV Shlyk1 , 1State Medical University of Rostov-on-Don - Rostov-on-Don - Russian Federation ,

Citation:

Purpose. Assessment of the factors of angiogenesis in patients with arterial hypertension (AH), coronary artery disease (CAD) and acute coronary syndrome (ACS).

Materials and methods: 82 patients and 19 healthy volunteers were examined. The patients were divided into three groups: I - 28 people with AH, mean age 55,00±1,80 years, II - 22 patients - patients with AH and CAD, mean age - 64,68±2,60 years, III - 32 people with AH and ACS - 32 patients, mean age, 48±1,84 years. To conduct the enzyme immunoassay, reagents Bender Medsystems (USA) VEGF were used. The concentration of the test substance was obtained by calculation from the optical density values using the MathCad program in accordance with the instructions of the reagent manufacturer. Statistical processing of data was carried out using statistical analysis program Statistica 6.0 (Statsoft, USA).

Results of the study: mean VEGF levels were not different in patients with AH and relatively healthy volunteers: 196,04±17,17 pg / ml in patients with AH (fluctuations from 22,04 to 834,05 pg / ml) and 176, 78±14,34 pg / ml in healthy volunteers, their scatter is much lower - from 56,23 to 303, 12 pg / ml. The level of endostatin was significantly higher among patients with elevated blood pressure than in the relatively healthy 313,73±13,34 and 97,42±7,25, with p <0,05, respectively. In patients with AH and ACS, the maximum values of VEGF are significantly lower in patients of group 1 (only AH), with no difference in the level of VEGF among patients with AH and CAD when comparing them with patients of the 1st and 3rd groups, i.e. they occupy an intermediate position. The maximum values of endostatin were among patients who underwent ACS, minimal - with CAD and intermediate - in patients of the 1st group, all the differences are reliable.

Conclusions: when comparing the levels of angiogenesis factors in blood, the survey showed that in patients with AH and ACS, the maximum values of VEGF are significantly lower in patients of Group I, the difference in VEGF level among patients with AH and CAD when comparing them with patients I and III groups were not identified, i.e. they occupy an intermediate position. The maximum values of endostatin were among patients who underwent ACS, minimal - with CAD and intermediate - in patients of Group I, all differences are reliable.



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are